Biotech: Page 63
-
Seagen shares sink as sales outlook of cancer drug disappoints
The biotech is predicting sales of Tukysa, its new breast cancer drug, will remain flat or fall in 2022 as competition increases from AstraZeneca's rival medicine Enhertu.
By Jacob Bell • Feb. 10, 2022 -
Editas' executive shake-up continues
Shares of the gene editing biotech slumped Tuesday on news that chief medical officer Lisa Michaels had joined a growing list of executive departures.
By Jacob Bell • Feb. 8, 2022 -
Explore the Trendline➔
National Institutes of Allergy and Infectious Diseases. (2016). "Human natural killer cell" [Micrograph]. Retrieved from Flickr.
TrendlineCell therapy
The continued emergence of CAR-T therapy has fueled research into next-generation approaches and new applications, such as its use in autoimmune diseases.
By BioPharma Dive staff -
Courtesy of Business Wire
Al Sandrock, former top Biogen scientist, to join drug discovery startup's board
Sandrock's appointment to Verge Genomics' board of directors follows about a week after the executive took up a similar post with Voyager Therapeutics.
By Ned Pagliarulo • Feb. 8, 2022 -
Spencer Platt via Getty Images
Deep Dive // Emerging biotech‘The music stopped’: Biotech rout leaves drug startups grounded as demand slumps for IPOs
For the first time in years, biotechs no longer had an easy path onto Wall Street, a market reversal that could change what the next generation of young drugmakers looks like.
By Ben Fidler • Feb. 7, 2022 -
Carol Highsmith. (2005). "Apex Bldg." [Photo]. Retrieved from Wikimedia Commons.
More federal regulators investigating Biogen Alzheimer's drug
In a regulatory filing, Biogen said the FTC and the SEC are looking for information about Aduhelm's approval and marketing, meaning the drug is now the focus of four government probes.
By Jacob Bell • Feb. 4, 2022 -
Courtesy of Intellia Therapeutics
Intellia, expanding in gene editing, buys startup Rewrite for $45M
Founded by University of California, Berkeley scientists, Rewrite is studying ways to expand the reach of gene editing beyond limitations of current technologies, including Intellia's.
By Ned Pagliarulo • Feb. 3, 2022 -
Permission granted by Biogen
Biogen's Alzheimer's drug sales remain slow as company warns of further cost cuts
Aduhelm sales totaled just $1 million in the fourth quarter as Biogen struggles to win over doctors and insurers. The company said it would reduce expenses by more than currently planned if Medicare limits coverage.
By Jacob Bell • Updated Feb. 3, 2022 -
Courtesy of Sarepta
Sarepta reveals gene editing alliance with biotech exploring alternative delivery methods
The collaboration with GenEdit, a South San Francisco startup developing new ways of delivering gene editing tools into the body, dates back to December 2020, but has recently begun to advance.
By Ned Pagliarulo • Feb. 1, 2022 -
Kubra Cavus via Getty Images
Pfizer stops development of once-promising heart drug, handing back rights to partner Ionis
Pfizer concluded the data didn't support advancing the ANGPTL3-targeting drug — for which it paid $250 million two years ago to acquire the rights — despite positive study results.
By Ned Pagliarulo • Jan. 31, 2022 -
Courtesy of Galapagos
Paul Stoffels, J&J's former top scientist, to lead Galapagos
Stoffels, who helped build Galapagos in its early days, is now taking helm of the biotech as it looks to recover from a recent series of setbacks.
By Kristin Jensen • Jan. 27, 2022 -
selvanegra via Getty Images
Touting a new way to drug an all-important family of proteins, a startup launches with $100M
Backed by some of biotech's most powerful investors, Septerna is looking to usher in the next chapter of medicines that act on G protein-coupled receptors.
By Jacob Bell • Jan. 27, 2022 -
Photo illustration by Maura Sadovi/BioPharma Dive; photograph by Carl Court via Getty Images
Moderna follows Pfizer in beginning trial of omicron vaccine
The study will test a version of the biotech's COVID-19 shot that's tailored to the infectious variant. New data, meanwhile, help affirm the benefit of a third dose of Moderna's current vaccine.
By Jonathan Gardner • Jan. 26, 2022 -
Sarah Silbiger via Getty Images
A biotech wins the first FDA drug approval in a rare type of eye cancer
U.K.-based Immunocore's treatment, known as Kimmtrak, is also the first T cell receptor drug to have reached market in the U.S. so far.
By Jonathan Gardner • Jan. 26, 2022 -
Permission granted by Cortexyme
Cortexyme to shift focus after FDA places hold on experimental Alzheimer's drug
While a recent trial of Cortexyme's drug had failed, the biotech was planning to move ahead with another study. Now the company is cutting costs and prioritizing an earlier-stage therapy.
By Ned Pagliarulo • Jan. 26, 2022 -
Justin Sullivan via Getty Images
Gilead's oncology plans take a hit as FDA stops tests of key cancer drug
U.S. regulators halted several studies of a drug Gilead paid almost $5 billion to acquire in 2020 after researchers observed an "apparent imbalance" of serious adverse reactions.
By Ben Fidler • Jan. 26, 2022 -
Meletios Verras via Getty Images
Gene editing startup Metagenomi raises $175M to advance research pipeline
The biotech raised the Series B round during "probably one of the worst biotech markets" emerging drugmakers have faced in some time, a Metagenomi executive told BioPharma Dive.
By Ned Pagliarulo • Jan. 25, 2022 -
Permission granted by Iowa Economic Development Authority
Sponsored by Iowa Economic Development AuthorityIowa's institutions on the leading edge of next-gen vaccines and therapies
Learn more about Iowa's efforts in the ongoing fight against pandemics and other threats to human and animal health.
Jan. 24, 2022 -
Cancer biotech Zymeworks to lay off more than 100 staff in restructuring
The biotech's newly minted CEO said the 25% workforce reduction should help make Zymeworks more financially stable as it focuses on developing experimental cancer drugs and forging new deals.
By Kristin Jensen • Jan. 20, 2022 -
Carol Highsmith. (2005). "Apex Bldg." [Photo]. Retrieved from Wikimedia Commons.
Antitrust regulators aim to revamp merger guidelines, signaling threat to health sector deals
The news sparked headlines about an attempt by regulators to target big tech, but it could have serious implications for healthcare, too.
By Samantha Liss • Jan. 19, 2022 -
Permission granted by ICON
Sponsored by ICONHow CRO venture capital relationships can help biotech fundraising
A CRO can offer numerous services to biopharma and medical device companies, from drug discovery all the way through to commercialization, pharmacovigilance and post-approval activities.
Jan. 18, 2022 -
Danielle Ternes/BioPharma Dive
JPM22: Aftershocks for Lilly, CRISPR versus CRISPR and Bluebird's crucial year
A restrictive Medicare decision on Alzheimer's drugs sent Lilly shares tumbling, while the CEO of Editas brushed off competitive threats to his company's gene editing technology.
By Ned Pagliarulo , Ben Fidler • Jan. 12, 2022 -
libre de droit via Getty Images
Amgen partners with Arrakis to develop drugs aimed at RNA
Arrakis, a specialist in designing oral drugs that target RNA, will receive $75 million under the deal, which could be worth "several billion dollars" more.
By Ned Pagliarulo • Jan. 11, 2022 -
Yujin Kim / MedTech Dive, original photo courtesy of U.S. Food and Drug Administration
5 questions facing the FDA in 2022
If Robert Califf wins Senate confirmation as expected, he will face a lengthy agenda as well as questions on Aduhelm controversy, accelerated approval and agency funding.
By Jonathan Gardner • Jan. 11, 2022 -
Danielle Ternes/BioPharma Dive
JPM22: Pfizer's big bet on mRNA, Biogen 'proven wrong' on Aduhelm price and the next cell therapies
The healthcare conference's first day brought a trio of mRNA deals from Pfizer, a rare admission from Biogen's CEO and new focus on what's next in cell therapy.
By Ned Pagliarulo , Jonathan Gardner , Jacob Bell • Jan. 10, 2022 -
Lisa Maree Williams via Getty Images
AstraZeneca adds to rare disease drug pipeline with Neurimmune deal
Neurimmune, which will license to AstraZeneca an early-stage treatment for a rare form of cardiomyopathy, is probably best known for its invention of the antibody that became Biogen's Alzheimer's drug Aduhelm.
By Ned Pagliarulo • Jan. 7, 2022
Previous
